NCT07050381 (pAVM-rFA) is a clinical trial in Arteriovenous Malformation of Central Nervous System, sponsored by The First Affiliated Hospital with Nanjing Medical University.

Who is sponsoring NCT07050381?

NCT07050381 is sponsored by The First Affiliated Hospital with Nanjing Medical University.

What condition does NCT07050381 study?

NCT07050381 studies Arteriovenous Malformation of Central Nervous System, Aneurysm, Ruptured, Aneurysmatic Subarachnoid Haemorrhage, Aneurysm Cerebral.

Is NCT07050381 still recruiting?

NCT07050381 is currently recruiting now. Last updated 3 July 2025.

Last reviewed 2025-07-03 · How we verify

NCT07050381: pAVM-rFA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Risk Factors Related to Rupture Flow-related Aneurysms in Posterior AVM

Recruiting now Last updated 3 July 2025

What this trial tests

trial in Arteriovenous Malformation of Central Nervous System in 200 participants. Currently enrolling.

Timeline

13 June 2025

Primary endpoint
31 August 2025

31 December 2026

Quick facts

Lead sponsor	The First Affiliated Hospital with Nanjing Medical University
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	200
Start date	13 June 2025
Primary completion	31 August 2025
Estimated completion	31 December 2026
Sites	2 locations across China

Conditions studied

Arteriovenous Malformation of Central Nervous System — all drugs for Arteriovenous Malformation of Central Nervous System →
Aneurysm, Ruptured — all drugs for Aneurysm, Ruptured →
Aneurysmatic Subarachnoid Haemorrhage — all drugs for Aneurysmatic Subarachnoid Haemorrhage →
Aneurysm Cerebral — all drugs for Aneurysm Cerebral →

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Who can join

Eligibility, any sex, with Arteriovenous Malformation of Central Nervous System or Aneurysm, Ruptured. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

AVMs have been reported to rupture at a formidable annual rate of 2% to 3% at natural progression, often resulting in longterm neurological deficits and poor functional outcomes.The reported risk of hemorrhagic presentation in patients with AVMs is 41% to 65%. While many studies suggest a correlation between higher hemorrhage risk and the concurrent presence of AVM and aneurysms, few authors have focused specifically on flow-related aneurysms alone. In many instances, the source of rupture is also unclear. Meta-analysis from 2016 suggested that 49.2% of hemorrhages were secondary to aneurysm rupture, 45% from AVM rupture, and 5.7% were undetermined.In a study of 302 patients, of which 52.6% had a hemorrhagic presentation, demonstrated a significant increase in rate of hemorrhage in those with flow-related aneurysms. Thus, it is necessary to figure out risk factors related to ruptured flow-related aneurysms in pAVM.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Risk factors for flow-related aneurysm rupture associated with posterior circulation arteriovenous malformation: a multicenter retrospective study.
Yifei W, Guangxi L, Chenyuan L, Shu C, et al · · 2025 · PMID 41368358 · DOI 10.3389/fneur.2025.1685261

Verify or expand the search:

Other The First Affiliated Hospital with Nanjing Medical University trials

Trials by the same sponsor.

NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07523789 — Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC · not yet recruiting
NCT07464756 — SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer · Phase 2 · not yet recruiting
NCT07482826 — Full-Endoscopic Decompression vs. Endoscopic Lumbar Fusion for Middle-Aged and Older Adults With Spinal Stenosis · NA · not yet recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07050381 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital with Nanjing Medical University
Last refreshed: 3 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07050381.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing